Cytovac performes in house research, GMP production, clinical trial and quality management. Clinical trials are performed in close collaboration with leading Scandinavian hospitals and doctors. The company employs a dedicated staff that has research experience within immunology and cell biology together with expertise within the fields of clinical research, pharmaceutical production and quality control.
The culture at CytoVac is open, forthcoming and professionally well-founded. All the employees are dedicated to the purpose of developing gentle and efficient ways to treat cancer.
Cytovac A/S was founded in 2008 by Bent Alsø, member of the board, Dr Alexei Kirkin and Dr Karine Dzhandzhougazyan. The technology behind the ALECSAT therapy is based on these two researchers’ basic research. The company is a limited company financed by private investors.
Parts of the scientific basis for this immunotherapy was initially developed in collaboration with the Danish Cancer Society, supported by private foundations. The Cancer Suciety is still a close collaboration partner.
In 2007, Dr Karine Dzhandzhugazyan and D. Alexei Kirkin took out the first patents for protection of the ALECSAT technology that is fully owned by CytoVac, and since then the patent portfolio has continuously been expanded.